Cartilage injury - autologous chondrocyte implantation (ACI) (review) (TA89)
Fast, easy summary view of NICE guidance on 'musculoskeletal conditions'
Autologous chondrocyte implantation (ACI) for the treatment of cartilage injury (review of existing guidance TA16)
ACI is not recommended for treating knee problems caused by damaged articular cartilage, unless it is used in studies that are designed to produce good-quality information about the results of the procedure. These results should include measuring any improvement in patients’ quality of life, and the benefits and risks of ACI over a long period of time.
If ACI is offered as part of a clinical study, the doctor should explain that there are uncertainties about the long-term benefits of this procedure and the possible risks, such as locking of the knee, infections and not being able to fully straighten the leg.
This guidance updates and replaces NICE technology appraisal 16 (published in December 2000)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: musculoskeletal conditions
This page was last updated: 12 February 2014
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.